These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 9739784)
1. Continuous infusion cisplatin and etoposide chemotherapy for cancer of unknown primary site (CUPS) in Taiwan, a region with a high prevalence of endemic viral infections. Liu JM; Chen YM; Chao Y; Liu SM; Tiu CM; Wu HW; Chiou TC; Hsieh RK; Chen LT; Whang-Peng J Jpn J Clin Oncol; 1998 Jul; 28(7):431-5. PubMed ID: 9739784 [TBL] [Abstract][Full Text] [Related]
2. Cisplatin plus oral etoposide in the treatment of patients with advanced small cell lung cancer. Japan Clinical Oncology Group. Asamoto H; Kawahara M; Iwami F; Kuba M; Furuse K; Tamura T; Saijo N; Shimoyama M Jpn J Clin Oncol; 1998 Dec; 28(12):745-8. PubMed ID: 9879292 [TBL] [Abstract][Full Text] [Related]
3. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529 [TBL] [Abstract][Full Text] [Related]
4. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470 [TBL] [Abstract][Full Text] [Related]
5. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725 [TBL] [Abstract][Full Text] [Related]
6. Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site. Karapetis CS; Yip D; Virik K; Strickland A; Ryder K; Cowling M; Harper PG Med Oncol; 2001; 18(1):23-32. PubMed ID: 11778966 [TBL] [Abstract][Full Text] [Related]
7. High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary. Gill I; Guaglianone P; Grunberg SM; Scholz M; Muggia FM Anticancer Res; 1991; 11(3):1231-5. PubMed ID: 1888154 [TBL] [Abstract][Full Text] [Related]
8. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site. Greco FA; Hainsworth JD Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278 [TBL] [Abstract][Full Text] [Related]
9. [Phase II study of a continuous five-day intravenous infusion of cisplatin and etoposide with concurrent chest radiation therapy in limited stage small cell lung cancer]. Sugita T; Matsunaga K; Kobayashi H; Horikawa S; Suzuki Y; Nishiyama H; Maekawa N; Matsumoto H; Okazaki M; Katagami N Gan To Kagaku Ryoho; 1994 Oct; 21(14):2479-83. PubMed ID: 7944494 [TBL] [Abstract][Full Text] [Related]
10. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers. Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591 [TBL] [Abstract][Full Text] [Related]
11. Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer. Remick SC; Chmura M; Bromberg C; Sporn J; Healey B; Hilstro J; DeConti RC; Horton J; Ruckdeschel JC; Harper GR Am J Clin Oncol; 1996 Apr; 19(2):125-31. PubMed ID: 8610634 [TBL] [Abstract][Full Text] [Related]
12. [Adriamycin, cisplatin, and etoposide combination chemotherapy for small cell lung cancer]. Irino S; Fujita J; Yamaji Y; Futami H; Hashimoto Y; Bungo M; Iuchi Y; Kamei M; Nakamura H; Hata Y Gan To Kagaku Ryoho; 1989 Jun; 16(6):2263-7. PubMed ID: 2544150 [TBL] [Abstract][Full Text] [Related]
13. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154 [TBL] [Abstract][Full Text] [Related]
14. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site. Greco FA; Johnson DH; Hainsworth JD Semin Oncol; 1992 Dec; 19(6 Suppl 13):14-8. PubMed ID: 1492223 [TBL] [Abstract][Full Text] [Related]
15. Preliminary study of efficacy of intravenous cisplatin plus oral etoposide in small cell lung cancer. Chewaskulyong B; Thongprasert S J Med Assoc Thai; 1998 Jan; 81(1):37-41. PubMed ID: 9470320 [TBL] [Abstract][Full Text] [Related]
16. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185 [TBL] [Abstract][Full Text] [Related]
17. Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Greco FA; Gray J; Burris HA; Erland JB; Morrissey LH; Hainsworth JD Cancer J; 2001; 7(3):203-12. PubMed ID: 11419028 [TBL] [Abstract][Full Text] [Related]
18. A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). Warner E; Goel R; Chang J; Chow W; Verma S; Dancey J; Franssen E; Dulude H; Girouard M; Correia J; Gallant G Br J Cancer; 1998 Jun; 77(12):2376-80. PubMed ID: 9649162 [TBL] [Abstract][Full Text] [Related]
19. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer. Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799 [TBL] [Abstract][Full Text] [Related]